Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?

Table 1 Changes in clinical assessments, bone mineral density and laboratory analysis following anti-TNF treatment in AS patients

	Baseline	6 months	12 months	P
BASDAI	5.11 ± 2.1	2.78 ± 2.4	2.78 ± 2.5	< 0.001
BASFI	5.40 ± 2.7	2.96 ± 2.6	2.85 ± 2.7	< 0.001
BASMI	4.06 ± 2.7	3.23 ± 2.6	3.07 ± 2.7	0.003
AsQoL, score	10.03 ± 5.2	6.43 ± 6.4	6.40 ± 6.05	0.001
ESR, mm/hr	23.75 ± 23.1	8.16 ± 15.6	7.3 ± 13.1	< 0.001
C-reactive protein, mg/dL	37.03 ± 47.9	3.35 ± 4.1	7.21 ± 20.1	< 0.001
MMP-3, ng/mL	48.6 ± 42.5	21.6 ± 22.5	23.3 ± 30.8	< 0.001
BMD lumbar spine, g/cm²	1.032 ± 0.175	1.049 ± 0.169	1.065 ± 0.169	< 0.001
BMD femoral neck, g/cm²	0.864 ± 0.160	0.865 ± 0.159	0.864 ± 0.161	0.051
BMD total femur, g/cm²	0.990 ± 0.165	0.986 ± 0.165	0.999 ± 0.171	0.981
Sclerostin, pmol/L	60.5 ± 32.7	67.1 ± 31.9	72.7 ± 32.3	< 0.001
Sclerostin binding to LRP6, OD₄₅₀	0.61 ± 0.13	ND	0.60 ± 0.14	0.472

Values are expressed as mean (SD). AS, ankylosing spondylitis; BASDAI, Bath AS Disease Activity Index; BASFI, Bath AS Functional Index; BASMI, Bath AS Metrology Index; ASQoL, AS quality of life questionnaire; BMD, bone mineral density; ESR, erythrocyte sedimentation rate; MMP-3, matrix metalloproteinase 3; LRP6, low-density lipoprotein receptor-related protein 6; OD, optical density; ND, not done.

ISSN: 1478-6362